Trial Profile
A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer and Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Rilimogene galvacirepvec (Primary) ; Rilimogene glafolivec (Primary) ; Rilimogene glafolivec (Primary) ; Granulocyte-macrophage colony-stimulating factors; Granulocyte-macrophage colony-stimulating factors
- Indications Prostate cancer
- Focus Therapeutic Use
- 01 Jun 2011 Results will be presented at the 47th Annual Meeting of the American Society of Oncology (ASCO-2011).
- 14 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.